药物成瘾是一种慢性复发性脑疾病，导致严重的医学、精神和社会经济问题。目前已获批上市抗成瘾药物以纳曲酮、美沙酮、丁丙诺啡为主。研发自身不成瘾且有效对抗复吸的、不良反应低的广谱性抗成瘾药物对于成瘾的防治具有重要意义。大麻二酚具有良好的抗成瘾、防复吸的药效学作用，可抗阿片类药物成瘾、抗可卡因和合成苯丙胺类物质成瘾、抗酒精成瘾、抗尼古丁成瘾、抗新型精神活性物质成瘾。总结了大麻二酚抗药物成瘾的临床前、临床研究进展，为多角度认识大麻二酚作为治疗药物成瘾的候选药物的潜力提供参考。

Drug addiction is a chronic recurrent brain disease that leads to serious medical, mental, and socio-economic problems. At present, the approved anti addiction drugs on the market are mainly naltrexone, methadone, and buprenorphine. Anti addiction drugs that are not addictive themselves and effectively in combating relapse with low adverse reactions are of great significance for the prevention and treatment of addiction. Cannabidiol has good pharmacological effects on anti addiction and anti relapse. Cannabidiol can resist addiction to opioid drugs, cocaine and synthetic amphetamine substances, alcohol, nicotine, and new psychoactive substances. This article summarizes the preclinical and clinical research progress of cannabidiol in treatment of drug addiction, providing reference for the potential of cannabidiol as a candidate drug for treating drug addiction from multiple perspectives.

R971

国家重点研发计划（2023YFC3304201）